Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance

BACKGROUND: Crizotinib has demonstrated favorable efficacy in patients with advanced ALK‐positive non‐small cell lung cancer (NSCLC). Unfortunately, the majority of ALK‐positive patients ultimately develop acquired resistance within one year after the initiation of crizotinib treatment; however, the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Xu, Haiyan, Yang, Guangjian, Yang, Lu, Yang, Yaning, Ma, Di, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Wang, Yan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500969/
https://ncbi.nlm.nih.gov/pubmed/30920172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados